Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiniferatoxin for Intractable Cancer-Induced Bone Pain
NCT02522611Phase 2Not yet recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Nov 2026
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of resiniferatoxin in cancer-induced bone pain (CIBP), sponsored by National Institute of Neurological Disorders and Stroke. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
resiniferatoxin
03
Conditions
cancer-induced bone pain (CIBP)
Beyond the preview
Go deeper on NCT02522611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522611.